March 11, 2026
CMIC Co., Ltd.
CMIC Earns SBT Certification for Its Greenhouse Gas Reduction Targets — Driving Forward Its Decarbonization Commitment
Tokyo, Japan — CMIC Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Shunji Katayama), the contract research organization (CRO) business of CMIC Group and a subsidiary of CMIC HOLDINGS Co., Ltd., jointly owned by Blackstone, has been officially certified by the Science Based Targets initiative (SBTi) for its greenhouse gas (GHG) emissions reduction goals.
This certification confirms that CMIC’s GHG reduction targets are in line with the Paris Agreement goal of limiting global warming to 1.5°C above pre-industrial levels.
■CMIC’s Approved GHG Reduction Targets for FY2030
- Scope 1 & 2: 48.2% reduction compared to FY2023 levels
- Scope 3: 25% reduction compared to FY2023 levels
These targets represent CMIC’s commitment to reducing GHG emissions across its entire supply chain, marking a significant step toward enhancing corporate sustainability and fulfilling its social responsibilities.
“As a company dedicated to supporting pharmaceutical development, minimizing environmental impact is one of our essential responsibilities,” said Shunji Katayama, President & CEO, CMIC Co., Ltd. “Building on the achievement of SBT certification, we will accelerate the optimization of our business processes, the use of renewable energy, and co-creation with our suppliers. While upholding quality and data integrity, we will steadily advance the simultaneous creation of business value and environmental value.”
Future Initiatives
CMIC will continue to strengthen its efforts to reduce GHG emissions while pursuing both business growth and environmental value creation, contributing to the realization of a decarbonized society.
CMIC’s GHG Emissions Over the Past Three Years (t-CO₂)
| Category | FY2023 | FY2024 | FY2025 |
| Scope 1 | 9 | 0 | 0 |
| Scope 2 | 1,503 | 972 | 969 |
| Scope 3 Upstream | 12,331 | 12,248 | 12,108 |
| Scope 3 Downstream | – | – | – |
| Total Emissions | 13,843 | 13,220 | 13,077 |
About CMIC Co., Ltd.
CMIC Co., Ltd., as the core company responsible for the CRO business within the CMIC Group, provides comprehensive support for pharmaceutical development through a broad range of services, including clinical trial consulting, monitoring, data management, biostatistics, and safety management, as well as regulatory submission support, post‑marketing surveillance (PMS), and database research. In addition to global capabilities, the company actively adopts digital technologies and new methodologies to deliver highly reliable development support that balances enhanced efficiency with improved quality.
For more information about CMIC, visit https://en.cmicgroup.com.
About CMIC Group
CMIC was founded in 1992 as the first contract research organization (CRO) in Japan. To enable pharmaceutical companies to develop better medicine sooner, we expanded our solutions to include contract development and manufacturing (CDMO), site support, and market solutions, supporting global companies to bring highly desired treatments to the Japanese market.
CMIC has also entered into the healthcare arena. Leveraging our vast experience and expertise in the medical industry, we offer solutions using a new ecosystem of healthcare to support the individuals and local governments. We strive to be a Personal Health Value Creator (PHVC) to meet our global customers’ needs in the U.S., Japan, and broader Asia. CMIC Group has over 7,700 employees and 28 sites globally.
For more information about CMIC Group and services, please visit our website: https://en.cmicgroup.com/
Media Contact
PR Group,
CMIC Co., Ltd.
E-mail: press@cmic.co.j
